A randomized double‐blind, placebo‐controlled clinical phase IIa trial on safety, immunomodulatory effects and pharmacokinetics of EA‐230 during experimental human endotoxaemia

AIMS: EA‐230 is a human chorionic gonadotropin hormone‐derived linear tetrapeptide, developed for the treatment of systemic inflammation‐related disorders. EA‐230 has shown promising immunomodulatory and tissue‐protective effects in animals and an excellent safety profile in human phase I studies th...

Descripción completa

Detalles Bibliográficos
Autores principales: van Groenendael, Roger, Kox, Matthijs, Leijte, Guus, Koeneman, Bouke, Gerretsen, Jelle, van Eijk, Lucas, Pickkers, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595370/
https://www.ncbi.nlm.nih.gov/pubmed/30919998
http://dx.doi.org/10.1111/bcp.13941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595370/
https://www.ncbi.nlm.nih.gov/pubmed/30919998
http://dx.doi.org/10.1111/bcp.13941

Ejemplares similares